关注
Jonathan Wagner
Jonathan Wagner
Professor of Pediatrics
在 cmh.edu 的电子邮件经过验证
标题
引用次数
引用次数
年份
Results of the FUEL Trial
DJ Goldberg, V Zak, BH Goldstein, KR Schumacher, J Rhodes, DJ Penny, ...
Circulation 141 (8), 641-651, 2020
1252020
Impact of SLCO1B1 Genotype on Pediatric Simvastatin Acid Pharmacokinetics
JB Wagner, S Abdel‐Rahman, L Van Haandel, A Gaedigk, R Gaedigk, ...
The Journal of Clinical Pharmacology 58 (6), 823-833, 2018
392018
PharmVar GeneFocus: SLCO1B1
LB Ramsey, L Gong, S Lee, JB Wagner, X Zhou, K Sangkuhl, SM Adams, ...
Clinical Pharmacology & Therapeutics 113 (4), 782-793, 2023
312023
Drug dose selection in pediatric obesity: available information for the most commonly prescribed drugs to children
KE Kyler, J Wagner, C Hosey-Cojocari, K Watt, V Shakhnovich
Pediatric Drugs 21 (5), 357-369, 2019
292019
Pediatric pharmacokinetics
J Wagner, SM Abdel-Rahman
Pediatrics in review 34 (6), 258-269, 2013
292013
Pediatric statin administration: navigating a frontier with limited data
J Wagner, SM Abdel-Rahman
The Journal of Pediatric Pharmacology and Therapeutics 21 (5), 380-403, 2016
212016
Impact of genetic variation on pravastatin systemic exposure in pediatric hypercholesterolemia
JB Wagner, S Abdel‐Rahman, R Gaedigk, A Gaedigk, G Raghuveer, ...
Clinical Pharmacology & Therapeutics 105 (6), 1501-1512, 2019
202019
Loss of consciousness in the young child
J Villafane, JR Miller, J Glickstein, JN Johnson, J Wagner, CS Snyder, ...
Pediatric cardiology 42, 234-254, 2021
182021
Considerations for implementing precision therapeutics for children
MJ McLaughlin, J Wagner, V Shahknovich, B Carleton, JS Leeder
Clinical and Translational Science 12 (2), 140-150, 2019
172019
Impact of SLCO1B1 Genetic Variation on Rosuvastatin Systemic Exposure in Pediatric Hypercholesterolemia
JB Wagner, S Abdel‐Rahman, A Gaedigk, R Gaedigk, G Raghuveer, ...
Clinical and Translational Science 13 (3), 628-637, 2020
142020
Efficacy of weight reduction on pediatric nonalcoholic fatty liver disease: opportunities to improve treatment outcomes through pharmacotherapy
CS Friesen, C Hosey-Cojocari, SS Chan, IL Csanaky, JB Wagner, ...
Frontiers in Endocrinology 12, 663351, 2021
132021
Pediatric pharmacogenomics: a systematic assessment of ontogeny and genetic variation to guide the design of statin studies in children
J Wagner, JS Leeder
Pediatric Clinics 59 (5), 1017-1037, 2012
132012
Developmental considerations for the use of naltrexone in children and adolescents
SL Stancil, S Abdel-Rahman, J Wagner
The Journal of Pediatric Pharmacology and Therapeutics 26 (7), 675-695, 2021
112021
The impact of cerebral embolization during infant cardiac surgery on neurodevelopmental outcomes at intermediate follow-up
RJ Naik, JB Wagner, D Chowdhury, ML Barnes, DS Wagner, KC Burson, ...
Perfusion 29 (5), 443-449, 2014
112014
Quantification of pravastatin acid, lactone and isomers in human plasma by UHPLC-MS/MS and its application to a pediatric pharmacokinetic study
L van Haandel, KT Gibson, JS Leeder, JB Wagner
Journal of Chromatography B 1012, 169-177, 2016
102016
A population pharmacokinetic model for simvastatin and its metabolites in children and adolescents
K Ogungbenro, JB Wagner, S Abdel-Rahman, JS Leeder, A Galetin
European journal of clinical pharmacology 75, 1227-1235, 2019
92019
Oseltamivir-warfarin interaction in hypoplastic left heart syndrome: case report and review
J Wagner, SM Abdel-Rahman
Pediatrics 135 (5), e1333-e1336, 2015
92015
Children are not small adults: specific findings in statin exposure and response in a growing population
JB Wagner
Clinical pharmacology and therapeutics 106 (2), 278, 2019
82019
Asymptomatic left ventricular myxoma in a 12-year-old male
M Chlebowski, J O'Brien, C Hertzenberg, J Wagner
Texas Heart Institute Journal 43 (3), 267-269, 2016
82016
Functional consequences of pravastatin isomerization on OATP1B1-mediated transport
JB Wagner, M Ruggiero, JS Leeder, B Hagenbuch
Drug Metabolism and Disposition 48 (11), 1192-1198, 2020
52020
系统目前无法执行此操作,请稍后再试。
文章 1–20